ESMO Preceptorship on Metastatic Bladder and Kidney Cancer
Application deadline: Tuesday 17 September 2019
The most influential oncology meeting in Europe, in partnership with the EACR.
IMPORTANT! Beware of fraudulent websites offering registration or accommodation!
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
At ESMO Congress 2018 in Munich, Women's cancers Patients Guides were presented in a talk-format session.
13 Sep 2019
Doxolipad, a hybrid medicine, contains the active substance doxorubicin
12 Sep 2019
The next research and innovation framework programme
10 Sep 2019
PURE findings reflect transition in the predominant causes of deaths in middle-age
09 Sep 2019
The review was triggered by data from several studies showing a higher number of skin cancer cases in patients using a gel for treating actinic...
06 Sep 2019
Third international consensus meeting-based guidelines
05 Sep 2019
Findings from an individual participant meta-analysis of the worldwide epidemiological evidence
Barcelona, Spain
27 Sep
- 01 Oct
2019
Lisbon, Portugal
11 Oct
- 12 Oct
2019
Lugano, Switzerland
11 Oct
- 12 Oct
2019
Lugano, Switzerland
17 Oct
- 18 Oct
2019
Barcelona, Spain
21 Oct
- 22 Oct
2019
Valencia, Spain
25 Oct
- 26 Oct
2019
